CM with high IL-6 levels induces PD-L1 expression through the STAT3 and AKT pathways, and breast cancer cells treated with high IL-6 CM exhibit resistance to chimeric antigen receptor T-cell (CAR-T) cell killing [96]. Here, IL6 is linked to breast cancer.